Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound 'Memory' imaging may reveal hidden heart ischemia

NCT ID NCT07762495

Diagnosis Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This trial tests whether a special ultrasound technique can detect heart muscle ischemia (reduced blood flow) in people with suspected acute coronary syndrome. The approach uses microbubbles that stick to activated immune cells and blood vessel linings, potentially revealing inflammation even after the ischemia has resolved. Researchers will compare the imaging results with a final diagnosis made by an expert committee to see how accurate the test is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Myocardial contrast echocardiography (MCE) molecular imaging with Sonazoid, a contrast agent containing microbubbles designed to stick to activated immune cells and blood vessel linings to reveal inflammation from ischemia.
What this could lead to
If it works, this could lead to a quick, bedside ultrasound test that helps doctors rapidly confirm or rule out a heart attack, potentially speeding up treatment and reducing unnecessary hospital stays.
What could go wrong
This is an early, proof-of-concept study with a small number of patients, so the imaging may not be accurate enough for routine use. There is also a small risk of allergic reactions to the contrast agent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years of age * Patients with possible or suspected ACS based on clinical criteria (history, ECG, laboratories) and HEART score \>3. Exclusion Criteria: * Cardiogenic shock * Inability to obtain consent * Severe heart failure (NYHA class IV) * Mechanical complication of MI (ischemic VSD, papillary muscle rupture, ventricular free wall rupture) * Ongoing life-threatening arrhythmias * Neutropenia (\<1,500/mm3) * Pregnancy * Lactation * Allergy to ultrasound contrast agents or eggs * History of autoimmune or inflammatory disease with myocardial involvement (SLE, sarcoidosis, giant cell myocarditis, etc.)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.